Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Yen-Shen LuEznal Izwadi Bin Mohd MahidinHamdy AzimYeşim EralpYoon Sim YapSeock-Ah ImJulie RihaniErhan GokmenAhmed El BastawisyNuri KaradurmusYueh Ni LimChun Sen LimLe Thanh DucWei-Pang ChungGovind Babu KKonstantin PenkovJames BowlesTeresa Delgar AlfaroJiwen WuMelissa GaoKhemaies SlimaneNagi S El SaghirPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
First-line ribociclib plus ET showed a significant PFS benefit, similar response rates, and better tolerability over combination CT in patients with clinically aggressive HR+/HER2- ABC.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- computed tomography
- induced pluripotent stem cells
- postmenopausal women
- open label
- image quality
- contrast enhanced
- locally advanced
- randomized controlled trial
- dual energy
- breast cancer risk
- magnetic resonance imaging
- young adults
- squamous cell carcinoma
- decision making
- double blind
- cell therapy
- early breast cancer
- chemotherapy induced